Ann: AXE partners with Hylid Diagnostics for Biochip development, page-36

Don't we eventually have to know who is going to market and sell it? AXE or Hylid. To me it looks like Hylid will.

here's the general state of play with medical devices courtesy of Google -

Here's a more detailed breakdown of IP royalties in the context of medical devices:

How Royalty Rates are Determined:

• Percentage of Sales Revenue:

  Royalties are usually calculated as a percentage of the net or gross revenue generated by the licensed intellectual property.
• Fixed vs. Tiered Rates:

  Royalty rates can be fixed for the duration of the license agreement or tiered, with rates adjusted based on sales volume or market conditions.
• Milestone Payments:

  In addition to royalties, the IP owner may negotiate for lump sum payments at specific milestones, such as signing the agreement, manufacturing a prototype, or achieving certain sales targets.
• 25% Rule:

  The 25% rule is a technique for determining royalties, which stipulates that a party selling a product or service based on another party's intellectual property must pay that party a royalty of 25% of the gross profit made from the sale, before taxes.

This last one would work well for us if Hylid sells the packaged product.